Novo Nordisk's Wegovy Pill Has Topped 5 Million Prescriptions. Is the Stock a Buy Now?

Novo Nordisk s new name, Novo, has no impact on the success of its Wegovy GLP-1 weight-loss pill. The drug is in high demand, with over five million prescriptions written. This is a significant milestone for the medication, which has proven more successful than the company's previous GLP-1 shot. The weight-loss category is crucial, as obesity and its health implications are a worldwide issue.

Novo Nordisk was the first to market in this space, and the drug's popularity has even led to generic competition entering the market. However, the company's earnings have suffered due to its strategy of selling at lower prices, which has impacted both revenue and earnings. While the global weight-loss opportunity is vast, there are concerns that a volume-driven model may not be sustainable in the long run.

More conservative investors may prefer to wait to see if Novo Nordisk's income statement improves before investing. Nevertheless, the stock's dividend yield is attractive at 4.4%, and its payout ratio is a reasonable 33%. For more aggressive investors, Novo Nordisk could present a buy opportunity with its high yield and potential for capital appreciation.

Despite the uncertainties surrounding the company's transition to a volume-driven model, the early success of Wegovy suggests that the strategy may be working. The stock's price-to-sales and price-to-earnings ratios are currently lower than their five-year averages, making it an appealing value play.